The Buzz Surrounding Canopy Rivers Inc. (TSX-V: RIV) (OTC: CNPOF)

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector.

Our Behind the Buzz Show Featuring
Canopy Rivers Inc. (TSX-V: RIV) (OTC: CNPOF) Corporate Overview

About Canopy Rivers

Canopy Rivers Inc., the venture capital affiliate of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), is an investment and strategic support platform focused on the emerging global cannabis industry.

The company has an established portfolio of diversified investments across several categories including licensed production,  processing, pharmaceutical formulation, brand development, distribution, cosmetics, data & technology, and media.

Investor Recap

2020E attributable EBITDA from joint ventures *

Current market value of public and private venture investments**

Cash for future investments ***

* Represents midpoint of estimated proportionate EBITDA for joint venture investments for CY 2020 based on Canopy Rivers’ ownership stake.
** Represents estimated market value for select public and private venture investments as at March 31, 2019.
*** Approximately $65 MM is unencumbered and available for new investments.







Canopy Rivers’ portfolio of  companies brings product, segment, geographic, and investment structure diversification. The company looks to invest in all segments of the cannabis value chain as well as aims to partner with expert management teams that bring track records of success.

Investments take the form of production-linked royalties, secured debt, newly formed joint ventures, and a variety of equity and equity-linked instruments. These various structures position Canopy Rivers with preferred economics that ascribe value to both financial and strategic considerations.

Current Portfolio

Relationship With Canopy Growth


Exposure to highly experienced operators in unique and specialized growth verticals and industry niches 

Access to new brands, new IP, craft producers, and ROFR / ROFO optionality on products, services, and offtake cannabis.


To portfolio companies: access to its distribution network, genetics, and strategic support 

To Canopy Rivers: access to deal flow, proprietary structures, and global reach.

Competitive Advantages


  • Origination of investment opportunities from deep network and knowledge of the industry
  • Access to unique structures and investment opportunities
    – Production linked royalty / debt
    – Newly formed joint ventures
    – Preferred economics


  • Strategic partnership with Canopy Growth, the world’s largest cannabis company
  • Global entrepreneurs, industry leaders and government officials


  • Finance professionals supported by a highly experienced team of technical cannabis professionals
  • Evaluation of over 1,500 opportunities resulting in in-depth knowledge and unparalleled insights into overall trends shaping the global cannabis industry


  • Retail distribution and CraftGrow (through Canopy Growth)
  • Supply offtake arrangements
  • R&D partnerships

Canopy Rivers offers diversified exposure to the burgeoning cannabis sector

May 28, 2019 - Canopy Growth subsidiary and Canopy Rivers portfolio company Vert Mirabel now fully licensed by Health Canada

Canopy Growth subsidiary and Canopy Rivers portfolio company Vert Mirabel now fully licensed by Health Canada

Les Serres Vert Cannabis Inc. ("Vert Mirabel"), a subsidiary of Canopy Growth Corporation and a portfolio company of Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF) ("Canopy Rivers") has received its final cultivation licence from Health Canada. All 700,000 sq. ft. of operating space at Vert Mirabel is now licensed for cannabis production. Vert Mirabel was established in December 2017 between Canopy Growth, Canopy Rivers, and Les Serres Stéphane Bertrand ("Bertrand").

"We are thrilled that the operational infrastructure at Vert Mirabel is now fully online with over 500,000 sq. ft. already in production," said Olivier Dufourmantelle, Chief Operating Officer, Canopy Rivers. "Vert Mirabel is a key asset for Canopy Rivers as it provides exposure to a commercially scaled source of locally grown, premium quality cannabis for distribution into Québec and across the country."

The licence for Vert Mirabel increases the facility's growing space by 190,000 sq. ft. It brings Canopy Growth's total Canadian licensed production footprint to approximately 4.6 million sq. ft, another step towards its nearly 5.6 million sq. ft. national platform. The Vert Mirabel facility leverages Bertrand's multi-generational greenhouse operational expertise to produce high-quality cannabis.

"The final licence for Vert Mirabel strengthens our operations and will allow us to increase supply to meet the recreational market demand," said Mark Zekulin, President and co-CEO, Canopy Growth. "From everyone at Canopy Growth, we congratulate the Bertrand family and their team for achieving a fully licensed, large-scale cannabis operation in under 18 months."

Bertrand is a large-scale greenhouse operator and, prior to converting to cannabis, it was the largest producer of pink tomatoes in Canada. "We are proud to announce that our venture with Canopy Growth and Canopy Rivers has reached this milestone," said Stéphane Bertrand. "Obtaining this licence will allow us to pursue our production goals in order to expand our footprint to meet the needs of the Québec market."

See full news release here:

May 21, 2019 - Canopy Rivers Portfolio Company Agripharm Awarded Outdoor Cultivation Licence

Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSXV: RIV) (OTC: CNPOF) is pleased to share that its portfolio company, Agripharm Corp. ("Agripharm"), has received its outdoor cultivation license from Health Canada. Agripharm will be growing its first outdoor crop this summer at its Creemore, Ontariolocation using award-winning genetics.

"We are pleased to see Agripharm diversify its operations and increase its growing capacity with the grant of this outdoor cultivation licence," said Oliver Dufourmantelle, Chief Operating Officer of Canopy Rivers. "Agripharm's outdoor production is ahead of the curve with support from Green House Brands, which provides decades of experience in choosing, and successfully growing, the best genetics for open-air crops."

Founded in 2013, Agripharm is home to both the first cannabis production facility built from the ground up and the first supercritical CO2 extraction lab in Canada. Agripharm is located in Creemore, Ontario, and operates out of an indoor facility that has been licensed for cannabis production since 2014. Agripharm is co-owned by SLANG Worldwide Inc. ("SLANG Worldwide") (CNSX: SLNG), Canopy Growth Corporation (TSX: WEED,NYSE: CGC) and Green House Holdings North America Inc. and received a strategic investment from Canopy Rivers. Agripharm has the exclusive Canadian rights to the intellectual property, strains and brands of Green House Seed Co., the preeminent global provider of cannabis genetics, and its sister brand Strain Hunters. Agripharm is also the Canadian distributor of SLANG Worldwide's portfolio of leading U.S. consumer cannabis brands including, O.penVAPEBakked, District Edibles, and Magic Buzz.

"With access to strains optimized for outdoor production from the world's leading genetics portfolio, Agripharm is well-positioned to significantly increase its production capacity for extraction," continued Dufourmantelle. "Agripharm has robust internal extraction capabilities primed to bring SLANG Worldwide's most popular U.S. consumer brands to the Canadian cannabis market."

As a strategic partner of Agripharm, Canopy Rivers provided the capital to finance the build-out of Agripharm's growing facilities in exchange for a long-term royalty interest subject to annual cash flow minimums. Canopy Rivers made its strategic investment in Agripharm in 2017, recognizing the strength of its extraction capabilities and its unique partnerships with Green House Seed Co. and SLANG Worldwide. For more information regarding the Company's investment in Agripharm, please refer to the joint management information circular of Canopy Rivers Corporation and the Company dated August 8, 2018, filed with Canadian securities regulators and available on the Company's profile on SEDAR at

See full news release here:

May 15, 2019 - Canopy Rivers Backs BioLumic - Shines Light on New AgTech for the Medical Cannabis Industry

Canopy Rivers Backs BioLumic - Shines Light on New AgTech for the Medical Cannabis Industry

BioLumic Ltd. ("BioLumic"), creators of a sustainable ultraviolet (UV) crop yield enhancement system, and Canopy Rivers Inc. ("Canopy Rivers") (TSXV: RIV), (OTC: CNPOF) today announced a strategic investment from Canopy Rivers. BioLumic extended the Finistere Ventures-led Series A financing round to include Canopy Rivers' strategic investment of US$1.5 million, closing the oversubscribed round at US$6.7 million. The financing was comprised of a tier-one investor roster that also included Rabo Food & Agri Innovation Fund and Radicle Growth acceleration fund.

This marks Canopy Rivers' first investment in agri-technologies, specifically focused on the promising fields of plant physiology and UV photobiology. With extensive global trials in traditional and high-value produce crops already underway, BioLumic will use the added investment to grow its team to support the acceleration and expansion of its UV light treatment initiatives, including applications in the medical cannabis market.

"Canopy Rivers' mission is to build and support a thriving global cannabis economy, and we are dedicated to identifying and investing in strategic technology players throughout the legal cannabis value chain," stated Mary Dimou, Director, Business Development, Canopy Rivers. "Led by an exceptional management team, BioLumic's groundbreaking, proprietary UV technology has the potential to significantly improve cannabis growth, vigor and yield – promising an environmentally friendly, GM-free cannabis crop through the power of light."

Already demonstrating game-changing results in produce-crop trials around the globe, BioLumic's UV light treatments deliver long-term crop benefits such as improved crop consistency, increased yield, drought tolerance, and disease and pest resistance. With the global legal cannabis market expected to top $146 billion by the end of 2025 and increasing legalization of cannabis usage and farming around the globe, BioLumic aims to help commercial producers cultivate stronger, healthier plants to meet the rising demand for cannabis and cannabis-derived products in the regulated medical cannabis market.

"Growers need more sustainable ways to meet global crop demands, and precision UV light treatments can safely activate important characteristics in seeds and  seedlings that make them more productive as they mature," said BioLumic CEO Warren Bebb. "Canopy Rivers' extensive network in the cannabis industry and its ecosystem of companies will open a new, strategic market for BioLumic. Given our results with other flowering crops, the cannabis plant is a natural fit for our technology."

Building out its data science and machine learning teams, BioLumic will use the funding to accelerate the research and commercialization of its UV light crop yield enhancement system – with a focus on developing cannabis-specific UV treatments to improve yield and increase the concentration of cannabinoids, such as cannabidiol (CBD). It will continue to focus on traditionally grown produce such as lettuce, broccoli, strawberries and tomatoes, and increase its focus on seed treatments for row crops. The company plans to explore indoor farming and protected-environment, high-value crops in the future.

Canopy Rivers is proud to collaborate with BioLumic and its leading agtech venture partners to extend BioLumic's commercial and propriety agri-technologies for potential application in the medical cannabis sector. Finistere Ventures, focused on agtech and supported by industry leaders like Bayer and Nutrien, works closely with its extensive network in the ag and food space to help commercialize innovations at a global scale. Rabo Food & Agri Innovation Fund was launched by Rabobank, a global leader in food and agriculture financing, and invests in high-potential, early-stage food and agriculture companies. 

Dr. Adrian Percy, newly appointed CTO of Finistere Ventures and the former head of R&D for the Crop Science Division of Bayer, has joined the Board as Chairman, while Finistere's Arama Kukutai will stay on as a Board Observer. As part of the investment, Canopy Rivers' Mary Dimou will join the BioLumic Board as an Observer. Dean Tilyard, CEO of The Factory in Palmerston North, New Zealand, will also join the Board.  

"It is exciting to consider the broad range of benefits that BioLumic technology can offer to both seed producers and growers across a range of crops – from improved yield and consistency to reduction, and potentially replacement, of certain chemical and biological inputs," noted Percy.

See full news release here:

May 9, 2019 - Canopy Rivers Announces Significant Supply Agreement Between PharmHouse and Canopy Growth

Canopy Rivers Announces Significant Supply Agreement Between PharmHouse and Canopy Growth

Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSXV: RIV) (OTC: CNPOF) is pleased to announce that its portfolio company PharmHouse Inc. ("PharmHouse") has entered into a second offtake agreement (the "Agreement") with Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NYSE: CGC) for the purchase of cannabis from its 1.3 million square foot greenhouse facility upon licensing. The Agreement commits an additional 20% of PharmHouse's flowering space to Canopy Growth for the next three years, in addition to the 10% that was originally committed in May 2018. The Agreement provides for the delivery to Canopy Growth of a minimum of 25,000 kg of cannabis per year and a maximum of 45,000 kg of cannabis per year.

"PharmHouse continues to show tremendous progress at the facility, and the joint venture is quickly developing as a key pillar for value creation and synergy within the Canopy Rivers portfolio ecosystem," said Olivier Dufourmantelle, Chief Operating Officer of Canopy Rivers. "Thanks to the collaborative contributions of our joint venture partners, the ongoing support and guidance of Canopy Rivers, and the strategic insight of Canopy Growth throughout the licensing process, we are excited to announce an incremental supply partnership that mutually benefits all three parties."

This new supply arrangement provides PharmHouse with additional revenue visibility and financial de-risking for a significant portion of the expected production from the flagship facility. Canopy Rivers holds a 49% equity interest in the PharmHouse joint venture and has played an active role in sourcing and negotiating production and supply agreements, which now cover approximately 50% of expected annual output. The incremental 50% of output remains unencumbered for the development of PharmHouse's own suite of brands and products.

"This offtake agreement represents a significant step forward for PharmHouse. By effectively committing and selling 50% of our near-term cannabis production, we favorably position PharmHouse for the development of a proprietary suite of products and brands and/or the pursuit of incremental contract manufacturing agreements," said Tony Abbas, General Manager of PharmHouse. "The fact that we are executing yet another agreement with an industry titan like Canopy Growth sends a strong signal about the quality of our operations and the confidence in our team's ability to deliver."

The 1.3 million square foot facility in Leamington represents the first stage of a planned global strategic relationship between Canopy Rivers and its PharmHouse joint venture partner, a company formed by the leading principals and operators of a North American agriculture conglomerate. The parties seek to leverage their relationship networks and respective strengths in cannabis, global commercial agriculture, marketing, and distribution to pursue regulated cannabis opportunities together on a global scale.

See full news release here:

May 3, 2019 - Canopy Rivers congratulates TerrAscend on receiving its EU GMP certification and new distribution agreement

Canopy Rivers congratulates TerrAscend on receiving its EU GMP certification and new distribution agreement

Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company TerrAscend Corp. ("TerrAscend") (CSE: TER) (OTCQX: TRSSF) on its announcement yesterday that its facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice ("GMP") certificate in accordance with the rules governing medicinal products in the European Union ("EU"). TerrAscend also entered into a comprehensive sales and distribution agreement with iuvo Therapeutics GmbH ("iuvo"), a German pharmaceutical wholesaler. 

Only medical cannabis from EU GMP certified facilities, or the equivalent, may be sold in the EU. The regulatory approach has been led by several of the larger EU countries and as such, pharmaceutical grade controls in production were an established requirement from the onset of medical cannabis legalization. Through iuvo, management at TerrAscend expects to begin shipping pharmaceutical-grade cannabis products into Germany.

"We applaud TerrAscend for achieving one of the highest and most rigorous levels of quality certification in the world," said Narbe Alexandrian, President of Canopy Rivers. "TerrAscend is now one of select Canadian licensed producers that have been issued EU GMP certificates, and with its new distribution arrangement with iuvo, becomes the first and only cannabis operator with sales in US, Canada, and Europe."

In October 2018, to accommodate TerrAscend's strategic pursuits internationally, including select opportunities in the United States, Canopy Rivers agreed to restructure its investment and waive certain restrictive covenants that were granted by TerrAscend, in connection with its original investment.

See full news release here:



Canopy Rivers Inc. (“Canopy Rivers”) (TSXV: RIV) and High Beauty, Inc. (“High Beauty”) are pleased to announce the completion of an investment by Canopy Rivers in High Beauty, creator of industry-leading cannabis beauty brand high. Canopy Rivers has subscribed for US$2.5 million of shares in High Beauty, representing 18.4% of the company on a fully diluted basis, including additional warrant coverage.

“Being supported by Canopy Rivers enables us to collaborate within the Canopy Rivers ecosystem and to focus our energy and passion on the creation of a robust new product line using cannabis-derived extracts,” said Melissa Jochim, a highly successful formulator and Founder of High Beauty. "Cannabis sativa seed oil is an untapped ingredient resource with amazing skincare benefits.  This partnership will allow us to scale High Beauty’s business much “higher” in a short time frame.”


“We have been actively pursuing opportunities in the health and beauty industry, guided by a growing consumer trend of brand new, innovative and functional beauty products. Enter high,” said Narbe Alexandrian, President of Canopy Rivers. “Led by Melissa Jochim, a repeat entrepreneur, preeminent formulator and brand developer coming from the natural, organic segment of the beauty industry, high has already captured mindshare and awareness of consumers - it has all the makings to continue to be a prominent brand in the cannabis-infused beauty market.”

See full news release here:




Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) is pleased to share that its portfolio company, James E. Wagner Cultivation Corporation (“JWC“) (TSXV: JWCA) (OTCQX: JWCAF), has received its cultivation licence from Health Canada for its Kitchener-based commercial scale production facility (“JWC2“). This second licence launches the initial phase of JWC2, a 345,000 square foot production and distribution complex where JWC is rolling out more than 130 individual production rooms utilizing JWC’s proprietary GrowthSTORM™ Dual Droplet cultivation platform and methodologies. With the newly licenced facility located just minutes from JWC’s already licenced pilot facility, JWC is well-positioned for an efficient ramp-up and expects to commence cannabis production at JWC2 immediately.

“While optimizing production methodologies at their already licenced pilot facility, JWC has concurrently built out and implemented refinements and learnings for production at commercial scale,” said Daniel Pearlstein, EVP, Strategy, of Canopy Rivers. “We are pleased to see Health Canada reward JWC for the quality of their operations, and their disciplined approach to expansion with the issuance of this second site licence.”


"We have seen strong demand for standardized, quality-controlled indoor cannabis within both the medical and adult use cannabis markets," continued Pearlstein. "Until now, JWC has focused on delivering an exceptional experience to a concentrated population of patients and through Canopy Growth's Spectrum Cannabis online store. With this second site licence in hand and the expanded production facility now online, JWC is well-positioned to bring their premium quality-controlled cannabis products to patient and consumer markets on a much larger scale."


See full news release here:



Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) congratulates Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth”) and its portfolio company, Spot Therapeutics Inc. (“Spot”), on receiving a cultivation license from Health Canada for its Fredericton-based production and distribution facility. The newly licensed facility will operate under the flagship Tweed banner and is another important pillar in the Canopy family of companies’ commitment to establishing a local presence, engaging local trades, and creating economic opportunities within the provinces and communities the companies serve.

In 2017, Canopy Growth solidified its expansion strategy in Atlantic Canada when it acquired Spot and made significant local funding commitments in collaboration with Canopy Rivers, ultimately resulting in Canopy Growth being rewarded with one of the first provincial supply contracts in the cannabis industry, pursuant to a landmark MOU with the government of New Brunswick.


“The long-term income stream from Spot, combined with our existing royalty portfolio, will further stabilize Canopy Rivers’ operating cash flow profile and provide us with additional financial resources to deploy as we continue to make investments in industry verticals we believe offer long-term strategic value for our portfolio partners and shareholders,” said Eddie Lucarelli, CFO of Canopy Rivers.


See full news release here:



Canopy Rivers Inc. (“Canopy Rivers”) (TSXV: RIV) and LeafLink, Inc. (“LeafLink”) are pleased to announce the establishment of LeafLink Services International ULC (“LeafLink International”), a new venture that exclusively licenses and leverages LeafLink’s dominant business-to-business (B2B) marketplace and supply chain technology platform for deployment throughout regulated international cannabis markets.

LeafLink is a software-as-a-service (SaaS) marketplace that simplifies the supply chain through its e-commerce platform. The company has a growing network of more than 950 cannabis brands, and penetration throughout ~2,800 cannabis retailers across 16 territories in the United States. LeafLink has established the single largest B2B marketplace for cannabis brands and facilitates more than US$900 million in gross merchandise value annually. Retailers use LeafLink for managing their wholesale inventory, enabling them to shop multiple vendors in one cart, view up-to-date product and brand menus, review historical and open orders, discover new products, and request samples. LeafLink further serves vendors by offering supplementary tools such as order management, a customer relationship management (CRM) platform, inventory tracking tools, and customized reporting systems, among other services.   


By creating this new joint venture, Canopy Rivers continues to expand its exposure across the cannabis value chain through a capital-light, market-leading B2B platform that is immediately scalable across legal jurisdictions. Canopy Rivers intends to integrate its network of complementary cannabis companies and global reach to drive growth for LeafLink International and assist in developing and deploying this technology as it continues to increase its global footprint.


See full news release here:



Canopy Rivers Inc. (the “Company” or “Canopy Rivers”) (TSXV: RIV) congratulates its portfolio company Headset, Inc. (“Headset”) on the formation of its landmark strategic alliance with Nielsen Holdings plc (“Nielsen”) (NYSE: NLSN). Yesterday, Nielsen and Headset together announced an alliance that will provide U.S. cannabis market data and analytics to consumer packaged goods (CPG) companies monitoring the cannabis space.

“This announcement from Headset and Nielsen validates our belief in the importance of data in the rapidly unfolding and brand-intensive cannabis industry,” said Narbe Alexandrian, President of Canopy Rivers. “Partnering with Nielsen, an S&P 500 company and global market leader in consumer data and insights, marks a significant step forward for Headset in its goal to help companies make more informed business decisions through data.”

Through their partnership, Headset and Nielsen will enable CPG companies to better understand and engage with the fast-changing and dynamic cannabis industry. Combining Nielsen’s consumer research capabilities with Headset's real-time retail point of sale data and proprietary software platform will deliver greater visibility and insight into market-leading trends, consumer sentiment, the competitive product landscape, and potential interaction points within CPG categories. The first product of the Headset and Nielsen relationship will be a U.S.-focused industry report exploring market dynamics, consumer perceptions and motivations, and insights into purchase dynamics. While initially focused on the U.S., Headset and Nielsen also plan on developing a full suite of capabilities for the Canadian market.

See full news release here:



Canopy Rivers Inc. (TSXV:RIV) (“Canopy Rivers” or the “Company”) is pleased to announce that it has closed its previously announced bought deal financing (the “Bought Deal”) of subordinated voting shares of the Company (the “Subordinated Voting Shares”) with a syndicate of underwriters (the “Underwriters”) led by CIBC Capital Markets (“CIBC”) and Eight Capital (together with CIBC, the “Joint Bookrunners”). The Bought Deal consisted of an aggregate of 13,225,000 Subordinated Voting Shares, which reflects the exercise in full of the Underwriters’ over-allotment option, at a price of $4.80 per Subordinated Voting Share (the “Issue Price”) for gross proceeds of approximately $63.5 million.

Concurrent with the Bought Deal, the Company completed the previously announced private placement (the “Private Placement” and together with the Bought Deal, the “Offering”) with Canopy Growth Corporation (“Canopy Growth”), the Company’s largest shareholder. Pursuant to the Private Placement, Canopy Growth purchased 6,250,000 Subordinated Voting Shares at the Issue Price for additional gross proceeds of $30.0 million. Prior to the Offering, Canopy Growth owned approximately 26.5% of the issued and outstanding shares of the Company on a non-diluted basis and, elected to subscribe under the Private Placement for more than its pro rata participation right. Following completion of the Offering, Canopy Growth’s ownership interest in the Company has increased to approximately 27.1% of the issued and outstanding shares of the Company on a non-diluted basis.  The Subordinated Voting Shares issued pursuant to the Private Placement are subject to a statutory hold period under Canadian securities legislation expiring on June 28, 2019, and statutory restrictions on the distribution of shares from the holdings of a control person.


See full news release here:



Canopy Rivers Inc. (the “Company” or “Canopy Rivers”) (TSXV: RIV) today released its financial results for the three and nine months ended December 31, 2018. The Company’s full Management's Discussion and Analysis (the “MD&A”) and unaudited condensed interim consolidated financial statements for the three and nine months ended December 31, 2018 are available on the Company’s profile on SEDAR at and on the Company’s website at All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

“We believe that Canopy Rivers has rapidly developed a strong position in the dynamic and fast-growing global cannabis industry,” said Bruce Linton, Chairman and Chief Executive Officer of Canopy Rivers. “By bringing focus and clarity to every investment decision and working alongside global market leader Canopy Growth, Canopy Rivers is responding to the greatest need in the cannabis industry – smart capital.”  


“With more than $55 million of capital deployed during the quarter, Canopy Rivers continues to position itself as a preeminent investment firm in the cannabis industry,” said Eddie Lucarelli, Chief Financial Officer of Canopy Rivers. “As we continue to see meaningful developments at our portfolio companies, the closing of our bought deal financing and strategic investment from Canopy Growth will add additional strength to our balance sheet. With a strong pipeline of investment opportunities and regulatory reform continuing around the world, Canopy Rivers is optimally positioned to continue to prudently deploy capital to the global cannabis sector.”


See full news release here:

  1. Catherine Dunne 2 months ago

    Connections through Canopy Growth provide opportunity for $RIV to thrive. I believe investing in CBD vendors would be the next big thing as CBD products require no regulation.

    • Eugene Honders 2 months ago

      The CBD market alone is a billion dollar market that has a variety of applications.

      • Tuan Pham 2 months ago

        interesting that the company has a vested interest in High Beauty as many Hemp companies have pesticides in their products. Very hard to find pesticide / chemical free – organic products in the hemp industry.

        • Richard L. 2 days ago

          As the cannabis/hemp product scene becomes more mainstream, soon enough there will be organic options available

      • Mark Mandell 2 months ago

        Growth in the US cannabis products market will be huge, into the tens of billions of dollars. Seven or eight of those will vaping; but how many will CBD be?

      • Paul Johnson 2 months ago

        the future of the healthcare market revolves around cannabis and the relief it provides patients

        • Zack Clayton 1 month ago

          Anyone in M&A in the cannabis industry or investing in multi-state operators should keep an eye on this hearing in Massachusetts today. Commissioners are making moves.

        • Bobby Axlerod 1 month ago

          My ex-wife suffered chronic migraine and her eventual relief came from medical cannabis. If you have not tried that, you should.

      • Alvin Patrelli 1 month ago

        pain, stress, anxiety, sleeping aid, balancing your metabolism and energy out. CBD has numerous recreational applications, not to mention the medical ones.

      • Johnson G. 3 weeks ago

        CBD Oil can provide a safe, but powerful natural treatment for many health issues such as anxiety, depression, & even heart disease just to name a few. Whenever I have muscle pain I have a cbd cream handy for almost immediate relief

      • Eric Sufert 1 week ago

        The Hemp Business Journal has predicted that the market for CBD will grow from $390 million in 2018 to approximately $1.3 billion by 2022

    • Bruce Tennen 4 weeks ago

      a lot of people use CBD to get the advantages of cannabis without that pesky THC

      • Vacher Jessie 2 weeks ago

        Awareness of the many health and wellness benefits of CBD has led to astounding growth in market value over the last year… and its just getting started. #Cannabis #Accounting #CBD

  2. Nathan I. Jazeup 2 months ago

    Futures are bloody I would suspect cannabis will take a dive tomorrow but anything with the name canopy should be more resilient than others

  3. Alexander Brangman 2 months ago

    strategic investments in the cannabis industry will increase when regulations are consistent within nations as a whole. For example, the U.S. has rules and regulations by state, when it is medically and recreationally legal across the nation, more investors will delve inside the cannabis industry.

    • Michel Charbenneau 2 months ago

      As of now, cannabis licenses are among one of the most important pieces to consider in the industry, whether your in cultivation or distribution & sales

  4. Angela Leung 2 months ago

    Recently volume has risen, along with a $4 break. Pharmhouse agreement with Canopy Growth definitely playing a part in this move.

    • Harry Velez 4 weeks ago

      sub $4, looking to pickup. I know $3.50 may be far fetched but I’m patient with $riv

      • Randy Frederick 3 weeks ago

        had your chance today, we will be back over $4 before the end of the week.

  5. James E. 2 months ago

    Am i late to the party? Nice rebound past few days. Only thing scaring me is this equities market and all of Trump talk on trade wars with china

    • Erica Weiss 1 month ago

      stable over $4 but I’m looking for a break and hold over $4.50. The Cannabis industry continues to grow as increased investments display that demand is rising.

    • Eric Sufert 1 month ago

      Trump needs to take a step back then two steps forward. Did you think China was just going to say ok I’ll give you what you want? The answer is no dummy. It will all work out in the end and everyone will be better off in the end. Wake up clown. I’m not sure what Trump’s true goal is with this but it is affecting the market immensely

      • Dillon Harper 3 weeks ago

        Joe Biden’s Cannabis Policy Would Be A Gift To Donald Trump In A General Election

  6. Benjamin Smith 4 weeks ago

    $RIV portfolio NAV/royalty stream will keep rising as canna goes int’l and other industry niches emerge

  7. Dillon Harper 4 weeks ago

    “significant collaboration and sharing of best practices exist not only between Rivers and the portfolio companies, but also among portfolio companies themselves, as they can relate to cultivation, genetics and, most importantly, consumer data” Canopy Rivers is not just a VC Company with multiple investments in the Cannabis Space.

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For canopy rivers inc, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: